The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.

The efficacy of an HIV vaccine to prevent infection is likely to depend on the genetic variation of the exposing virus. This paper addresses the problem of using data on the HIV sequences that infect vaccine efficacy trial participants to (1) test for vaccine efficacy more powerfully than procedures that ignore the sequence data and (2) evaluate the dependence of vaccine efficacy on the divergence of infecting HIV strains from the HIV strain that is contained in the vaccine. Because hundreds of amino acid sites in each HIV genome are sequenced, it is natural to treat the genetic divergence as a continuous mark variable that accompanies each failure (infection) time. Problems (1) and (2) can then be approached by testing whether the ratio of the mark-specific hazard functions for the vaccine and placebo groups is unity or independent of the mark. We develop nonparametric and semiparametric tests for these null hypotheses and nonparametric techniques for estimating the mark-specific relative risks. The asymptotic properties of the procedures are established. In addition, the methods are studied in simulations and are applied to HIV genetic sequence data collected in the first HIV vaccine efficacy trial.

[1]  Peter B. Gilbert.  Large sample theory of maximum likelihood estimates in semiparametric biased sampling models , 2000 .

[2]  M E Halloran,et al.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines. , 1997, American journal of epidemiology.

[3]  B. Graham.  Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[4]  Subhash R. Lele,et al.  Biometrika Trust Maximum Likelihood Estimation in Semiparametric Selection Bias Models with Application to AIDS Vaccine , 2010 .

[5]  Mei-Jie Zhang,et al.  Cumulative regression function tests for regression models for longitudinal data , 1998 .

[6]  Yanqing Sun.  Generalized nonparametric test procedures for comparing multiple cause-specific hazard rates , 2001 .

[7]  Zhiliang Ying,et al.  Towards a general asymptotic theory for Cox model with staggered entry , 1997 .

[8]  H. Müller,et al.  Kernel estimation of regression functions , 1979 .

[9]  Peter B. Gilbert,et al.  Tests for Comparing Mark-Specific Hazards and Cumulative Incidence Functions , 2004, Lifetime data analysis.

[10]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[11]  J. Wellner,et al.  Empirical Processes with Applications to Statistics , 2009 .

[12]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[13]  Theo Gasser,et al.  Smoothing Techniques for Curve Estimation , 1979 .

[14]  M E Halloran,et al.  Interpretation and estimation of vaccine efficacy under heterogeneity. , 1992, American journal of epidemiology.

[15]  I. McKeague,et al.  Identification of Nonlinear Time Series from First Order Cumulative Characteristics , 1994 .

[16]  Michael R Kosorok,et al.  Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations , 2002, Biometrics.

[17]  Peter J. Bickel,et al.  Convergence Criteria for Multiparameter Stochastic Processes and Some Applications , 1971 .

[18]  Brian S. Yandell,et al.  Nonparametric Inference for Rates with Censored Survival Data , 1983 .

[19]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[20]  P. Billingsley,et al.  Convergence of Probability Measures , 1969 .

[21]  P. Diggle,et al.  Kernel estimation of relative risk , 1995 .

[22]  S. Self,et al.  Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. , 2001, Journal of clinical epidemiology.

[23]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[24]  Thomas A. Louis,et al.  Nonparametric estimation of the joint distribution of survival time and mark variables , 1998 .

[25]  Subhash R. Lele,et al.  Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials , 1999 .

[26]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[27]  Zhiliang Ying,et al.  Semiparametric and Nonparametric Regression Analysis of Longitudinal Data , 2001 .

[28]  J. Klein,et al.  Statistical Models Based On Counting Process , 1994 .